Tejas Savant
Stock Analyst at Morgan Stanley
(2.19)
# 2,530
Out of 4,814 analysts
226
Total ratings
37.78%
Success rate
-6.28%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $1.78 | +181.69% | 13 | Mar 25, 2025 | |
| GRAL GRAIL | Maintains: Equal-Weight | $16 → $20 | $27.24 | -26.58% | 2 | Mar 18, 2025 | |
| TEM Tempus AI | Maintains: Overweight | $50 → $60 | $40.45 | +48.33% | 2 | Mar 6, 2025 | |
| NTRA Natera | Maintains: Overweight | $176 → $185 | $148.08 | +24.93% | 13 | Mar 5, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $28 → $26 | $7.51 | +246.21% | 13 | Feb 14, 2025 | |
| IQV IQVIA Holdings | Maintains: Overweight | $245 → $250 | $143.91 | +73.72% | 11 | Feb 11, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $150 → $136 | $71.16 | +91.12% | 7 | Feb 11, 2025 | |
| AVTR Avantor | Maintains: Overweight | $27 → $25 | $15.40 | +62.34% | 16 | Feb 10, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $647 → $678 | $436.79 | +55.22% | 14 | Jan 31, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $84 → $82 | $57.55 | +42.48% | 8 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $22.03 | +4.40% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $31.76 | -11.84% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $7.63 | +175.23% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.17 | +70.94% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $3 | $1.10 | +172.73% | 10 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $7.85 | +409.88% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $3.66 | +91.52% | 8 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $9.54 | +78.20% | 12 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $10 | $7.33 | +36.52% | 11 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $16 | $5.55 | +188.29% | 1 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.75 | +698.93% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $2.85 | +250.88% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.37 | +16.03% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $3.20 | +56.49% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.97 | +407.61% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $45.18 | +61.58% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $105.93 | +136.00% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.56 | +792.22% | 5 | May 12, 2022 |
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.78
Upside: +181.69%
GRAIL
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $27.24
Upside: -26.58%
Tempus AI
Mar 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $40.45
Upside: +48.33%
Natera
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $148.08
Upside: +24.93%
10x Genomics
Feb 14, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $7.51
Upside: +246.21%
IQVIA Holdings
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $143.91
Upside: +73.72%
Illumina
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $150 → $136
Current: $71.16
Upside: +91.12%
Avantor
Feb 10, 2025
Maintains: Overweight
Price Target: $27 → $25
Current: $15.40
Upside: +62.34%
Thermo Fisher Scientific
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $436.79
Upside: +55.22%
Hologic
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $84 → $82
Current: $57.55
Upside: +42.48%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $22.03
Upside: +4.40%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $31.76
Upside: -11.84%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $7.63
Upside: +175.23%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.17
Upside: +70.94%
Aug 6, 2024
Downgrades: Equal-Weight
Price Target: $4 → $3
Current: $1.10
Upside: +172.73%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $7.85
Upside: +409.88%
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $3.66
Upside: +91.52%
Nov 8, 2023
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $9.54
Upside: +78.20%
Oct 24, 2023
Maintains: Equal-Weight
Price Target: $13 → $10
Current: $7.33
Upside: +36.52%
Aug 17, 2023
Initiates: Equal-Weight
Price Target: $16
Current: $5.55
Upside: +188.29%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.75
Upside: +698.93%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $2.85
Upside: +250.88%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.37
Upside: +16.03%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $3.20
Upside: +56.49%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.97
Upside: +407.61%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $45.18
Upside: +61.58%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $105.93
Upside: +136.00%
May 12, 2022
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.56
Upside: +792.22%